A special issue of The American Journal of Managed Care® answers questions asked by payers through studies that compare adherence and cost-effectiveness of drugs within a class.
Do people with diabetes who use long-acting insulin have lower overall healthcare costs? Does forcing a patient with rheumatoid arthritis to switch biologics for nonmedical reasons create other costs?
Questions like these are top-of-mind for payers and pharmacy benefit managers this time of year as they decide which drugs will be on formulary for 2019. A special pharmacy benefits issue of The American Journal of Managed Care® published this month examines a range of topics in health economics outcomes research, which decision makers are evaluating more than ever.
This issue includes:
About The American Journal of Managed Care®:
The American Journal of Managed Care® (AJMC®) is a peer-reviewed, MEDLINE-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision makers as they work to promote the efficient delivery of high-quality care. AJMC.com is the essential website for managed care professionals, distributing industry updates daily to leading stakeholders. Other titles in the AJMC® family include The American Journal of Accountable Care®, and two evidence-based series, Evidence-Based Oncology™and Evidence-Based Diabetes Management™. These comprehensive offerings bring together stakeholder views from payers, providers, policymakers and other industry leaders in managed care. To order reprints of articles appearing in AJMC® publications, please contact Jeff Prescott at 609-716-7777, ext. 331.
Theresa Burek, 609-716-7777